

ETIC Reaches Decision on Purchase of Debt from Kishimoto Clinical Laboratory and Related Company

March 10th, 2011

Enterprise Turnaround Initiative Corporation of Japan

The Enterprise Turnaround Initiative Corporation of Japan (“ETIC”), following its decision on December 9th, 2010 to provide support to Kishimoto Clinical Laboratory and Dotou Clinical Laboratory, Inc. (hereafter collectively “Kishimoto Laboratories”) under Article 25, Clause 4 of the Enterprise Turnaround Initiative Corporation of Japan Act (Act 63, of 2009, hereafter “the ETIC Act”) today, under Article 31, Clause 1 of the same act, resolved that it should not purchase debt owed by Kishimoto Laboratories.

1. Names of persons or companies concerned

Kishimoto Clinical Laboratory and Doutou Clinical Laboratory, Inc.

2. Amount of financial support

Approximately 7,600 million yen*

*The exact amount of support provided by related financial institutions will be decided as part of the special liquidation proceedings, which will be implemented after the completion of the company separation of Kishimoto Clinical Laboratories' operations.

3. Treatment of general trade creditors

This decision on the purchase of debt involves agreement between ETIC and the financial institutions providing loans to Kishimoto Laboratories. There will continue to be no impact on general trade creditors.

—Ends—